Key market opportunities for GLP-1 analogues include growth in the oral administration segment, expanding presence in Asia-Pacific and emerging markets, and strategic partnerships. Regulatory ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

Assistant Controller of Patents (C.A. (COMM.IPD-PAT) 76/2022), the Delhi High Court upheld the refusal of a patent ...

Sun Pharma has received approval from the Drugs Controller General of India to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 receptor ...

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.